This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2024 Remove Biosimilars Remove Generic Medicine Related Topics
Chemotherapy Pharmaceutical Companies Vaccines Pharmaceutical Companies Hospitals More Related Topics >
article thumbnail

CHMP meeting highlights: April 2024

European Pharmaceutical Review

APRIL 30, 2024

CHMP biosimilar recommendations A positive opinion for Tofidence (tocilizumab) was adopted by the committee, indicated for rheumatoid arthritis, COVID-19, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Biosimilars 89
Biosimilars Generic Medicine Chemotherapy Hospitals 89
article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

Generic Medicine 88
Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 88
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 33,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024